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Abstract
In antibody humanization, CDRs from a 'donor' antibody are often grafted onto a
human framework selected by high sequence identity with the donor. In our own
humanization experiments, we have found that species information is often incorrect.
Here  we  take  three  mouse  antibodies  and  perform  BLAST  searches  against
sequences annotated as being human. We find that the first genuine human hits for
the six chains  appear  at  positions  30,  4,  11,  24,  18 and 29 in  the hit  lists.  This
illustrates  both  the  need  for  caution  in  performing  humanization  and  for
improvements in annotation.
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Since the 1980s, the humanization of antibody sequences has become a necessary prerequisite to the
development of therapeutic antibodies derived from monoclonals or antibody libraries of rodent
(mouse or rat) or other species (e.g. rabbit). In general, the approach to humanization is to graft the
'complementarity  determining regions'  (CDRs) from a donor antibody (the non-human antibody
having  the  required  specificity)  onto  a  human  acceptor  framework.  The  earliest  humanization
attempts made use of one of the few existing human antibodies (Fab fragments or Bence-Jones
light-chain  dimers  from  myeloma  patients)  whose  structures  were  known.  Initially,  limited
framework substitutions in the human acceptor framework were necessary to restore binding to the
humanized rodent  variable  region.  The low level  of  substitution  required  (only one  framework
change in the heavy chain during humanization of CAMPATH (Riechmann  et  al.,  1988) and a
single  heavy  chain  residue  contact  identified,  but  not  implemented,  in  an  anti-lysozyme
humanization (Verhoeyen et al., 1988)) was likely due to a stroke of good luck since subsequently,
other  rodent  antibodies  have  required  a  significant  number  of  framework  changes  to  restore
complete binding (Queen et al., 1989, for example).
Since the early humanization experiments by the Winter group, several academic and biotechnology
company groups have published methods that range from targeting framework residues within a
certain distance of a CDR residue to essentially 'look and see' methods that try to make best guesses
at potentially important CDR/framework interactions by inspection of the x-ray structure, but which
are often limited by lack of structural data (Tsurushita et al., 2005). Numerous methods have been
proposed involving subtle nuances on existing protocols as well as more radical approaches. These
include molecular modelling to identify necessary framework changes (Queen et al., 1989; Carter
et  al.,  1992),  guided  selection  using  phage  display  (Jespers  et  al.,  1994),  variable  region
'resurfacing'  (Roguska  et  al.,  1994),  'superhumanization'  (Tan  et  al.,  2002;  Mader  and  Kunert,
2010), germline humanization (Pelat et al., 2008; Bernett et al., 2010), methods based on comparing
rodent and human sequence and structural data (Covaceuszach et al., 2012), consensus frameworks
(Couto  et al., 1995, for example), use of consensus framework positions shown to be critical for
CDR conformation and for which 'back to mouse' data were publicly available (Haidar et al., 2012),
co-optimization  of  CDRs and framework (Wu  et  al.,  1999),  redesign  of  the  CDRs rather  than
making framework changes (Hanf  et al.,  2014), and others. In addition,  web-based tools to aid
humanization strategies are available such as those of Martin (www.abysis.org) and Olimpieri et
al. (2015).
A requirement  for most,  if  not  all,  the humanization methods described in  the literature is  that
human heavy and light chain sequences that are potential acceptors for the donor CDRs are actually
'human'. Antibody sequences are submitted to a number of sequence databases and are supposedly
checked  and  correctly  annotated.  Until  July  2000,  the  most  accurate  source  of  such  sequence
annotation was the Kabat 'Sequences of Immunological Interest' – an online update of the classic
book (Kabat et al., 1991). Currently, antibody sequences are contained in IMGT, Genbank/EMBL-
ENA/DDBJ  (and  their  protein  translations,  Genpept  and  UniProtKB/trEMBL)  and  the  Protein
Databank. With the exception of IMGT, these are general resources containing DNA and protein
sequences and structures.  Resources such as SACS (Allcorn and Martin, 2002), AbDb (Ferdous &
Martin, in preparation) and SabDab (Dunbar  et al., 2014) extract antibody information from the
PDB, while  EMBLIG (Couch,  Porter,  Swindells  and Martin,  in  preparation)  does  the same for
EMBL-ENA data. It is worth noting that UniProtKB/SwissProt, probably the best annotated protein
sequence database, does not contain antibody sequences beyond a few examples.
Examples of 'header' information retrieved from such databases are shown in Figure 1. From the
'organism' assignment, the reader can determine whether or not the sequence is human, rodent or
from another species. Or can they? An equally important question is whether these data can be
extracted automatically and reliably by a computer program. 
In our own humanization studies (which use a combination of structure, overall sequence identity,
unusual framework sequence, unusual residues at particular positions and CDR/framework contact
analysis) when performing BLAST searches against supposedly human sequences from KABAT,
EMBL-ENA and the PDB, we have observed systematic errors in species assignment. As with many
approaches, we start by identifying a human acceptor sequence with high sequence identity to the
(often mouse) donor sequence (Queen et al., 1989). Thus a BLAST search is performed, using the
donor  sequence  of  interest,  against  a  database  of  human  sequences.  Inevitably,  if  the  donor
sequence is mouse and there are any mouse sequences mis-annotated as being human, these will be
extracted at the top of the BLAST hit list.
Here  we  present  three  examples  where  we  have  taken  well-known  publicly-available  mouse
antibody sequences – Gloop2 (Darsley and Rees, 1985), HyHel-5 (Smith-Gill et al., 1982) and 4D5
(Carter  et al., 1992) – and searched them against a database of antibody sequences annotated as
being human. A local BLAST database was created containing sequences annotated as human from
Kabat, IMGT, EMBLIG (derived from EMBL-ENA) and the PDB. UniProtKB/SwissProt could not
be used because of its lack of antibody sequences. Counts of sequences from the different sources
are provided in Supplementary File DatabaseContent.pdf Extraction of appropriate sequences
from these resources relied on a protein chain being annotated as being human, but excluding cases
of chains that have species information clearly indicating that they are chimeric or were a synthetic
construct (e.g. PDB entries 1BBJ, 1BVL, 4XTR). BLASTP was then used to search the mouse
antibody sequences against this database. 
The hits  obtained from such BLAST searches  were  cross-checked  by a  further  online  BLAST
search  of  each  hit  against  the  IMGT  Domain  Display  reference  sequences
(www.imgt.org/BlastSearch)  and  by  calculation  of  'humanness'  scores  (Abhinandan  and
Martin, 2007). Further manual investigation of the original source papers was then carried out.
Analysis of the BLAST results
The BLAST search results, showing the first two pages of hits for the three antibodies, are shown in
Supplementary File BlastHits.pdf. 
For the Gloop2 heavy chain, the top two hits are from PDB entry 3DGG, a mouse monoclonal
antibody produced in a human embryonic kidney cell line (HEK 293T). The third hit, PDB entry
3D85, is a chimeric antibody with mouse V-regions and human constant regions (Beyer et al., 2008)
as is the 20th hit, CAT05563.1 from patent WO2006126069. The fourth–eighth hits are humanized
mouse antibodies from patents WO2010061360 and WO2008047242. The ninth and 10th hits are
from PDB entry 1AXS, a mouse catalytic monoclonal antibody (Ulrich et al., 1997), while the 11th
and 12th hits are from PDB entry 3DIF, another mouse antibody expressed in HEK 293T cells.
Overall,  the first 27 entries are identified as mouse when searching against the IMGT reference
sequences. The 28th and 29th entries, CAI54212.1 and K049980, are ambiguous when searched
against the IMGT reference sequences. For CAI54212.1, the top hit in the IMGT reference set is
mouse, the next two are human and the fourth is from Macaca mulatta. For K049980, the top four
hits in the IMGT reference set are all mouse, but the fifth is human. Checking the original literature
(CAI54212.1: Patent EP1491632A2; K049980: Kashmiri  et al. (1995)), it turns out that both are
humanized antibodies. The first true human hit is 30th in the list from PDB entry 3HC0.
For the Gloop2 light chain, the top two entries are both mouse catalytic monoclonal antibodies. The
third entry is a mouse monoclonal antibody against digoxin (Lemeulle et al., 1998). The first bona
fide human light chain is the fourth hit (JX027410).
For the HyHEL-5 heavy chain, the top two hits are from PDB entry 3DIF, a mouse monoclonal. The
next sequence, 4UOM is reported in the literature to be the human antibody F5, but we believe it
may be a mouse sequence (see below). It is described in the same paper as humanized antibody
4B4C-4 (hit  number  46,  chain  A from PDB entry  4UOK).  The  next  seven  hits  are  all  mouse
monoclonals. The first true human antibody is the 11th hit, 4QCI which is derived from the HuCal
Gold human library, but this is followed by 3SQO, a humanized mouse antibody (J16). 
For the HyHEL-5 light chain, the first nine hits are mouse monoclonal antibodies. The 10th hit,
4UOK, is the humanized light chain partner of the heavy chain discussed above. The next hit (Chain
L from PDB entry 4IDJ) is a human sequence (Foletti  et al., 2013), but this seems to be a rather
unusual sequence since the next 12 hits all appear to be mouse. Using the IMGT reference set, the
source of the next hit, CBM42819.1 which is 20th in the list, is ambiguous. The top IMGT reference
set hit is mouse, the second is human and the next six are mouse. The sequence comes from patent
WO2010052556 and is, in fact, a humanized antibody. The next (21st) hit (chain L from PDB entry
1MIM) is a chimeric antibody with mouse variable domains while the 22nd (CAT05561.1) is mouse
and the 23rd is 4UOM which, as above, is described in the literature as human, but which we
believe may be mouse. The next hit, chain X from PDB entry 4K7P, appears to be the first genuine
human hit appearing 24th in the list. 
For the 4D5 heavy chain, none of the 17 top entries is from a bona fide human antibody. The first
two hits (2RCS and 1AJ7 from the PDB) are mouse catalytic antibodies (to establish this requires
following up second order references). In fact the sequence annotation for both 1AJ7 and 2RCS
indicates (incorrectly) that the heavy chain is human and the light chain is mouse. Of the remaining
hits in the top 17, 1FVC, 1FVD and 1FVE are humanized versions of mouse antibody 4D5; 4HKZ,
4UB0 are mutational studies on existing antibodies cetuximab (a chimeric antibody having a mouse
variable region) and trastuzumab (a humanized mouse antibody); 3BE1, 4IOI and 4HJG are also the
humanized version of mouse antibody 4D5, trastuzumab; and 1HKL and 1GAF are mouse catalytic
antibodies.  The  16th  hit,  CS490801.1,  is  a  humanized  mouse  antibody.  For  the  17th  hit,
CAM57950.1,  the  assignment  was  ambiguous  based  on  a  search  against  the  IMGT reference
sequences: the first hit was a mouse sequence while the next three were all human. Like the other
ambiguous hits described above, it also turns out to be a humanized mouse antibody. The first true
human hit is chain A from PDB entry 3B9V coming 18th in the list.
Finally, for the 4D5 light chain, the top two hits from mouse PDB entry 3DIF appear to be another
case which has been mis-annotated as human because it was expressed in HEK 293T cells. This is
followed by 10 sequences which are humanized mouse sequences, three PDB entries (1FVC, 1FVD
and 1FVE) from structural  studies  of  humanized 4D5 sequences  (trastuzumab)  and PDB entry
4UB0 (chimeric cetuximab). The next hits (17th and 18th in the list), AX375917 and CAD26809,
are from a patent that describes both chimeric and humanized sequences. The 19th to 22nd hits
(1FVE and 1FVD from the PDB) are also humanized. This is followed by six mouse, humanized
and chimeric sequences before the first human hit, chain L from PDB entry 3GRW, which is ranked
29th in the list.
What can be seen from the typical database headers shown in Figure 1 and the examples discussed
above is that the unsuspecting BLASTer will receive a long list of sequences for each antibody
chain frequently misleadingly designated as originating from  Homo sapiens. Selection of any of
these sequences on the assumption they are human could have serious consequences if the antibody
is on a therapeutic track and if the provenance is not rigorously pursued. Potentially, this could lead
to wasted time and money unless the error is identified quickly. It would be a potential  'horror
hamatoxicus',  to misquote Ehrlich, if such a mouse-based sequence made it as far as the clinic.
Establishing provenance however is not a trivial task. Many sequences are derived from patents
where details of the human framework used are not always provided and may be further obscured
by the presence of back mutations that are also not always described.
There  appear  to  be  two  major  sources  of  errors  that  should  be  easy  to  fix  given  sufficient
cooperation between those who deposit  sequences  and the teams that  annotate  them. First,  if  a
sequence is a chimeric antibody that contains non-human (typically mouse) variable domains and
human constant regions, it tends to be annotated as Homo sapiens. Similarly humanized antibodies
(with non-human CDRs and human variable domain frameworks and constant domains) are also
generally  annotated as human. This is  clearly incorrect:  such sequences should be annotated as
coming from the two species, or be indicated as artificial constructs. Second, there are a number of
instances in the PDB where mouse antibodies expressed in a human cell line (typically HEK 293T
cells) are annotated as human. It is not clear where the error comes from in these instances, but it is
possible that the species information has not been provided by the authors and some automated
algorithm recognizes the word 'human'.
It should be noted that the new formats for PDB files (the XML PDBML format and mmCIF files),
recognize the fact that meta-data were not clearly or fully described in the 'legacy' PDB file format
and allow more precise information to be presented. However, the problems described above are
still present in the mmCIF files for all entries discussed (see Supplementary File mmCIF.pdf).
As mentioned above, some more complex difficulties in establishing provenance are exemplified by
entries 4UOM and 4UOK in the PDB (see the heavy and light chain searches for HyHEL-5 in
Supplementary File  BlastHits.pdf). The 4UOM structure is described as the F5 Fab bound to
the alphavirus Venezuelan equine encephalitis virus (VEEV) and is described in Porta et al. (2014).
The earlier production of antibody F5 from a human bone marrow library is described in Hunt et al.
(2010).  This  paper  also  describes  mouse  monoclonal  antibodies,  one  of  which,  3B4C-4,  was
humanized and was also the subject of the structural study by Porta et al. with PDB code 4UOK.
The heavy chain (chain A) of PDB file 4UOK, (the humanized mouse antibody 3B4C-4 bound to
VEEV) has a reasonable humanness score (Abhinandan and Martin, 2007) of –0.7 and a search
against IMGT suggests it is most similar to human sequences. 4UOK was originally annotated as
mouse,  but  this  was changed to human in October  2014 as  is  currently  generally  the  case for
humanized sequences in the PDB. 
Strangely  however,  the  protein  sequence  of  the  heavy  chain  of  4UOM  (described  as  human
antibody F5)  has  a  lower humanness  score of  –0.953 and a  search  against  the  IMGT Domain
Display reference set suggests it is a mouse heavy chain. What is more, the CDRs of the heavy
chains in 4UOK and 4UOM are identical (see Figure 2), while the frameworks have a different
sequence  as  do  the  light  chains.  Thus,  in  attempting  to  pull  together  these  various  threads  of
information, this leads us to believe that, contrary to the database information, PDB entry 4UOM is
actually  the  mouse  sequence  of  3B4C-4  and  4UOK  is  the  humanized  heavy  chain  with  an
undetermined light chain. However, we cannot be sure and have not been able unambiguously to
establish their provenance. To be clear, we in no way question the validity of the published work, or
of the databases  themselves,  but merely wish to point out that  it  is  well  known that  databases
contain errors.  
Establishing the provenance of antibody sequences requires not just the normal scientist's tools, but
also the skills of a detective and a historian. Even then, certain sequences may remain ill-defined.
This situation needs to be resolved, particularly if people wish to generate automated algorithms for
antibody humanization.  As a  solution  to  this  problem, we would like  to  suggest  the following
modifications to the way in which antibody chain sequences are submitted to, and catalogued by,
sequence databases:
 First, authors must be required to provide clear and unambiguous species information.  For
new submissions, provision of such information must be a requirement of all  successful
submissions.
 Second,  where antibodies  are  chimeric  or  humanized,  a  standard way of  indicating  this
information  must  be provided by the  databases.  Some PDB entries,  such as  1GAF and
1AXS,  have  species  information  that  states  they  are  human,  but  do  provide  additional
information to state that it is in fact a chimeric (see Figure 3a and b.) However, this is free
text  information  and  the  format  is  different  between  entries  so  cannot  be  parsed
automatically. The same issues are present in the mmCIF versions of the files. Other entries
contain organism information for both species (e.g. PDB files 1BBJ, 4KAQ, 4MA3) and
were easily excluded from the searches performed here (see Figure 3c). 
 Third, there needs to be a thorough review of current database entries to correct species
information. Where possible, confirmation should be sort from authors for entries that have
had automatic  species annotation and, in other cases, database annotators need to check
original literature. At a minimum, there needs to be a record of where the species annotation
has come from (author, annotator, text mining, or elsewhere).
Conclusions
We hope this analysis will be helpful to researchers humanizing antibodies using standard antibody
sequence databases. Of course, the concept of database errors is not new, but in the antibody field,
the  consequences  of  erroneous  species  annotation  can  be  annoying,  costly  and  potentially
dangerous. We hope this analysis will allow database managers and annotators to take a serious
look at methods of sequence description. Automated classification by software will only resolve the
issues we have identified if the software is sufficiently 'intelligent', and the fact that many sequences
are artificial constructs and do not have a single species origin must be acknowledged in a standard
way in the annotations.  While species  annotation is a particular  problem for antibodies,  similar
problems are almost certainly present in database entries for other proteins. The authors are happy
to be contacted for further suggestions on how to improve this  particular  problem for antibody
sequences.
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Figure Legends
Figure 1 Relevant extracts from databank headers for example entries labelled as Homo sapiens but
which are actually mouse antibody chains. a) 3DGG (PDB) Actual: Mouse monoclonal antibody
expressed in human cell line; b) 3D85 (PDB) Actual: Mouse monoclonal V-regions as part of a
chimeric antibody; c) 1AXS (PDB) Actual: Mouse monoclonal antibody; d) CAT05563.1 (EMBL-
ENA)  Actual:  Chimeric  antibody  with  mouse  V-regions  and  human  constant  regions;
e) 041427/1C10 (Kabat) Actual: Mouse monoclonal against digoxin.
Figure 2 Sequence alignment of the heavy chains of the antibodies in PDB files 4UOK and 4UOM
numbered according to the Chothia numbering scheme and indicating the CDRs.
Figure  3 Relevant  species  ('SOURCE')  information  from  PDB  files  a) 1GAF  and  b) 1AXS
containing chimeric antibodies. While the key annotation lines state that the sequence is human,
additional  information  shows  that  it  is  chimeric.  c) 1BBJ  has  more  informative  key  species
annotation lines that show clearly that the chain is chimeric.
Figure 1
a)
HEADER    IMMUNE SYSTEM                           13-JUN-08   3DGG              
TITLE     CRYSTAL STRUCTURE OF FABOX108                                         
COMPND    MOL_ID: 1;                                                            
COMPND   2 MOLECULE: FABOX108 LIGHT CHAIN FRAGMENT;                             
COMPND   6 MOL_ID: 2;                                                           
COMPND   7 MOLECULE: FABOX108 HEAVY CHAIN FRAGMENT;                             
SOURCE    MOL_ID: 1;                                                            
SOURCE   2 ORGANISM_SCIENTIFIC: HOMO SAPIENS;                                   
SOURCE  10 MOL_ID: 2;                                                           
SOURCE  11 ORGANISM_SCIENTIFIC: HOMO SAPIENS;                                   
b)
HEADER    IMMUNE SYSTEM/CYTOKINE                  22-MAY-08   3D85              
TITLE     CRYSTAL STRUCTURE OF IL-23 IN COMPLEX WITH NEUTRALIZING FAB           
COMPND    MOL_ID: 1;                                                            
COMPND   2 MOLECULE: FAB OF ANTIBODY 7G10, LIGHT CHAIN;                         
COMPND   5 MOL_ID: 2;                                                           
COMPND   6 MOLECULE: FAB OF ANTIBODY 7G10, HEAVY CHAIN;                         
SOURCE    MOL_ID: 1;                                                            
SOURCE   2 ORGANISM_SCIENTIFIC: HOMO SAPIENS;                                   
SOURCE   5 MOL_ID: 2;                                                           
SOURCE   6 ORGANISM_SCIENTIFIC: HOMO SAPIENS;                                   
c)
HEADER    CATALYTIC ANTIBODY                      20-OCT-97   1AXS              
TITLE     MATURE OXY-COPE CATALYTIC ANTIBODY WITH HAPTEN                        
COMPND    MOL_ID: 1;                                                            
COMPND   2 MOLECULE: OXY-COPE CATALYTIC ANTIBODY;                               
COMPND   7 MOL_ID: 2;                                                           
COMPND   8 MOLECULE: OXY-COPE CATALYTIC ANTIBODY;                               
SOURCE    MOL_ID: 1;                                                            
SOURCE   3 ORGANISM_SCIENTIFIC: HOMO SAPIENS;                                   
SOURCE  21 MOL_ID: 2;                                                           
SOURCE  23 ORGANISM_SCIENTIFIC: HOMO SAPIENS;                                   
d)
LOCUS       FB985353                1413 bp    DNA     linear   PAT 14-DEC-2008
DEFINITION  Sequence 3 from Patent WO2006126069.
ACCESSION   FB985353
VERSION     FB985353.1  GI:218044635
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
e)
KADBID      041427
CREATD      11/16/98
DEFINI      IG KAPPA LIGHT CHAIN VARIABLE REGION
SPECIE      human
AANAME      1C10'CL
NNNAME      1C10
Figure 2
Light
              10        20        30            40        50        60    
     .........|.........|.........|ABCD.........|.........|.........|.....
4uok DIELTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGIPVRFSGS
4uom -------PHSASGPPDQTVTISCSGSSSNIEG--NTVNWYQQFPGKAPQLLIYGKDQRPSGVPDRFSAS
                            ***************               *******         
                            CDR-L1                        CDR-L2          
         70        80        90          100     
     ....|.........|.........|.....AB....|...... 
4uok GSGTDFTLNIHPVEEEDAATYYCQQSNEDP--FTFGSGTKLEI 
4uom KSGTSASLTISGLQAEDEADYYCAAWDDSLNGWVFGGGTKLTV 
                            ***********          
                            CDR-L3               
Heavy
              10        20        30        40        50         60    
     .........|.........|.........|.........|.........|..A.......|.....
4uok --QLVQSGAEVKKPGATVKISCKVSGYTFTDYYINWMQQAPGKGLEWIGRIYPGYGNTKYNDKFKG
4uom EVQLQQSGPELVKPGASVKISCKASGYTFTDYYINWMKQKPGQGLEWIGRIYPGYGNTKYNDKFKG
                                   *****              *****************
                                   CDR-H1             CDR-H2          
                                         99            
         70        80           90       |101      110 
     ....|.........|..ABC.......|........||........|.. 
4uok RVTLTADTSTDTAYMELSSLRSEDTAVYFCARSLTFFDVWGQGTMVTVSS
4uom KATLTEDTSSNTAYMQLNSLTSEDTAVYFCARSLTFFDVWGAGTTVTVSS
                                     *******           
                                     CDR-H3            
Figure 3
a) 1GAF
SOURCE    MOL_ID: 1;                                                            
SOURCE   2 FRAGMENT: CONSTANT DOMAINS OF LIGHT AND HEAVY CHAINS;                
SOURCE   3 ORGANISM_SCIENTIFIC: HOMO SAPIENS;                                   
SOURCE   4 ORGANISM_COMMON: HUMAN;                                              
SOURCE   5 ORGANISM_TAXID: 9606;                                                
SOURCE   9 OTHER_DETAILS: EACH CHAIN IS A FUSION POLYPEPTIDE WHICH IS           
SOURCE  10 PART HUMAN AND PART MOUSE;                                           
b) 1AXS
SOURCE    MOL_ID: 1;                                                            
SOURCE   2 FRAGMENT: CHAIN L, A, 108 - 211, CHAIN H, B, 114 - 214;              
SOURCE   3 ORGANISM_SCIENTIFIC: HOMO SAPIENS;                                   
SOURCE   4 ORGANISM_COMMON: HUMAN;                                              
SOURCE   5 ORGANISM_TAXID: 9606;                                                
SOURCE  17 OTHER_DETAILS: THE PROTEIN WAS PRODUCED AS CHIMERIC FAB              
SOURCE  18 FRAGMENT. THE CONSTANT DOMAINS ARE HUMAN, THE VARIABLE               
SOURCE  19 DOMAINS ARE MURINE.
c) 1BBJ
SOURCE    MOL_ID: 1;                                                            
SOURCE   2 ORGANISM_SCIENTIFIC: MUS MUSCULUS, HOMO SAPIENS;                     
SOURCE   3 ORGANISM_TAXID: 10090, 9606;                                         
